Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.73 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL973410 | 1.00 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL969359 | 1.00 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL973408 | 1.00 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL971949 | 1.00 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL8025793 | 0.94 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL6465998 | 0.94 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL4016537 | 0.94 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL41203 | 0.94 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL18948 | 0.94 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL7204032 | 0.94 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| WO-2024089666-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE | MACFARLAN SMITH LIMITED (GB) | 2024-05-02 | — | — | WO | disclosed |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| EP-1644019-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | New River Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000334-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885TAAR1 161/4885 |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885TAAR1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.